# Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

> **NCT05066685** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 18457 (actual)

## Conditions studied

- Age-related Macular Degeneration (AMD)

## Interventions

- **OTHER:** All participants

## Key facts

- **NCT ID:** NCT05066685
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-11
- **Primary completion:** 2020-09-25
- **Final completion:** 2020-09-25
- **Target enrollment:** 18457 (ACTUAL)
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05066685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05066685, "Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05066685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*